Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can computers accurately measure lung scarring? new study aims to find out

NCT ID NCT06743022

Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether automated software can consistently measure the amount of lung scarring (interstitial lung disease) on chest CT scans. Researchers will scan 150 adults with known lung scarring twice in a row to see if the measurements match. The goal is to improve the accuracy and reliability of these automated tools for better disease monitoring.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to more reliable and consistent automated measurements of lung scarring, helping doctors better track disease progression.
What could go wrong
This is an early reproducibility study, not a treatment trial. It may show variability that limits clinical use, and results may not apply to all types of ILD.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Known interstitial lung disease as part of idiopathic pulmonary fibrosis or connective tissue disease * Followed in one of the participating hospitals * Requiring a chest CT as part of a scheduled assessment * Affiliated to a French national social security * Informed consent Exclusion Criteria: * Acute exacerbation of ILD * Pregnancy * Inability to hold an apnea for 10 seconds * Patients in the exclusion period after a previous research * Need for additional procubitus or expiratory images

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary fibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis interstitial lung disease lung disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Interstitial lung disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHP - Bichat Hospital - Pneumology

    RECRUITING

    Paris, IDF, 75018, France

  • APHP - Bichat hospital - Radiology

    RECRUITING

    Paris, IDF, 75010, France

  • APHP - Bichat hospital - Rheumatology

    RECRUITING

    Paris, IDF, 75010, France

  • APHP - Cochin Hospital - Internal medicine

    RECRUITING

    Paris, IDF, 75014, France

  • APHP - Cochin Hospital - Pneumology

    RECRUITING

    Paris, IDF, 75014, France

  • APHP - Cochin Hospital - Radiology

    RECRUITING

    Paris, IDF, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.